What question did this study set out to answer?

The research aims to evaluate the safety and efficacy of switching between adalimumab and its biosimilars in patients with inflammatory bowel disease.

January 23, 2026Journal of Crohn s and Colitis

P0676Safety and Effectiveness of Multi-Switch between Adalimumab Originator and Biosimilars in Inflammatory Bowel Disease: A Multicenter (SUSTAIN) Study

View Full Paper

Ask AI

Bookmark

The research aims to evaluate the safety and efficacy of switching between adalimumab and its biosimilars in patients with inflammatory bowel disease.
Conducted a retrospective chart review of patients with inflammatory bowel disease from 2015 to 2025.
Included patients receiving adalimumab-adaz or adalimumab-atto.
Classified patients into two groups based on their switching patterns: group A (one switch) and group B (multiple switches).
Assessed primary outcomes focused on safety and adverse events, and secondary outcomes on clinical efficacy.
Out of 237 patients, 95.4% in group A and 93.6% in group B achieved sustained clinical remission.
Sustained normalization of inflammatory markers was seen in 91.5% of group A and 92.3% of group B.
No treatment-emergent adverse events or significant infections reported in either group.
Older age and prior immunomodulator use were significant predictors of switching.

Authors

MSM ShehabKing Abdullah Petroleum Studies and Research Center AAA AlmajdiMubarak Al Kabeer Hospital IAIsraa AbdullahMubarak Al Kabeer Hospital

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Multicenter study explores safety and efficacy of switching biologics in IBD, indicating favorable outcomes.

Cite This Study

Shehab et al. (2026) studied this question.

synapsesocial.com/papers/69730f59c8125b09b0d1f2de https://doi.org/10.1093/ecco-jcc/jjaf231.857

View Full Paper

Ask AI

Bookmark

P0676Safety and Effectiveness of Multi-Switch between Adalimumab Originator and Biosimilars in Inflammatory Bowel Disease: A Multicenter (SUSTAIN) Study

Key Points

Discussion

Implication

Cite This Study

P0676Safety and Effectiveness of Multi-Switch between Adalimumab Originator and Biosimilars in Inflammatory Bowel Disease: A Multicenter (SUSTAIN) Study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider